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Summary
Albuminuria is strongly associated with renal and cardio-
vascular outcomes independently of renal function level.
However, the pathophysiology of these associations is de-
bated. In chronic kidney disease (CKD), phosphate reten-
tion participates in cardiovascular events and increased
cardiovascular mortality. We hypothesised that albumin-
uria may modulate tubular phosphate handling by the kid-
ney. To verify this hypothesis, we first studied the asso-
ciation between phosphataemia and albuminuria in chil-
dren with nephrotic syndrome and in adults with CKD. In
both cases, higher albuminuria was associated with high-
er phosphate level, independently of glomerular filtration
rate. We further tried to decipher the molecular mech-
anisms of these observations. Using animal models of
nephrotic proteinuria, we could show that albuminuric rats
and mice had abnormally elevated sodium-phosphate api-
cal co-transporter expression, despite elevated fibroblast
growth factor 23 (FGF23). The FGF23 downstream path-
way was inhibited despite elevated FGF23 levels. Klotho
protein expression was also lower in proteinuric animals
compared to controls. Finally, albumin had no direct ef-
fects on phosphate transport in cells. Altogether, we show
that albuminuria induces alteration of phosphate tubular
handling, independently of glomerular filtration rate. The
mechanisms involved appear to include Klotho down-reg-
ulation and resistance to FGF23. This observation may
link albuminuria to increased cardiovascular disease via
altered phosphate handling. Finally, this observation
opens up further opportunities to better understand the link
between albuminuria, Klotho, FGF23 and phosphate han-
dling.
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The predictive value of proteinuria/albumin-
uria in chronic kidney disease (CKD)
Healthy urine is devoid of significant amount of albumin,
and contains only low levels of some physiologically se-
creted proteins, such as uromodulin [1]. For several years,
the presence of excessive protein in the urine (mainly albu-
min) has been linked to the prognosis of renal function, in
both at-risk patients and in the general population [2–5]. In
addition to renal complications, albuminuria is also strong-
ly predictive of cardiovascular disease and mortality [2, 3,
6, 7], independently of glomerular filtration rate (GFR).
This has led to the inclusion of albuminuria in addition to
estimated GFR in the definition of chronic kidney disease
(CKD) [8, 9].
The strong predictive value of albuminuria for CKD pro-
gression is not contested [2–5]. However, the causal role of
albuminuria in CKD progression is not unanimously rec-
ognized among nephrologists. Indeed, the belief that al-
buminuria could be only a marker of glomerular injury,
leading to fibrosis, is still quite popular. However, several
lines of evidence clearly demonstrate that albumin or other
filtered proteins have pro-inflammatory, pro-apoptotic and
pro-fibrotic effects on both proximal and distal tubular
cells [10–12]. Whereas absorption of albumin is mediated
by the albumin/cubulin system in the proximal tubule [1,
13, 14], the route of absorption of albumin in the distal
nephron is unclear and the 24p3R could play a role [15,
16]. The detrimental role of albumin on tubular cells may
secondarily induce tubulointerstitial fibrosis. Indeed, sev-
eral recent diverse observations convincingly show that in-
jury to tubular cells alone, in the absence of glomerular le-
sions, may lead to kidney interstitial fibrosis, and likely not
through epithelial to mesenchymal transition [17, 18].
How albuminuria and proteinuria are related to cardiovas-
cular risk is even more uncertain. Although this strong
relationship suggests that albuminuria should be consid-
ered as a cardiovascular risk marker, its causative role in
the pathophysiology of cardiovascular lesions is undeter-
mined. Importantly, decreasing albuminuria by either ACE
inhibitors or more recently, via SGLT2 inhibitors, reduces
both renal and cardiovascular risks [19, 20]. Albuminuria
may be the signature of endothelial injury, and therefore
indicate diffuse endothelial lesions associated with cardio-
vascular disease [21, 22]. In contrast, albuminuria may
play a direct pathophysiological role, directly increasing
cardiovascular disease risk.
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Phosphate retention and cardiovascular mor-
tality in kidney disease
CKD is associated with a major increase in cardiovascular
events and mortality. This association is explained by a
high prevalence of traditional risks factors in CKD pa-
tients, such as diabetes and hypertension for example.
However, some non-traditional cardiovascular risk factors
are specific to CKD patients. Among those, abnormal
phosphate handling related to decreased renal filtration
may play an important role.
Phosphate is absorbed by the gut. The main sources of
phosphate in the diet include protein-rich and pr-processed
foods due to the presence of preservatives. Phosphate is
mostly passively absorbed in the intestine. The bones are
the major reservoir for phosphate in the body. Excess phos-
phate ingested is excreted in the urine to maintain a neutral
daily phosphate balance [23, 24].
Most of the phosphate is filtered at the glomerulus. More
than 85% is reabsorbed in the proximal tubule by sodium/
phosphate co-transporters (mainly NPT2a and NPT2c in
humans). Major hormonal regulators of tubular phosphate
reabsorption include parathormone (PTH) and fibroblast
growth factor 23 (FGF23). PTH increases phosphaturia
by inducing endocytosis and degradation of sodium/phos-
phate co-transporters in the proximal tubule. PTH is main-
ly secreted in response to changes in calcaemia, and to a
lesser extent to phosphataemia. FGF23 is a phosphaturic
hormone secreted by osteocytes and osteoblasts in re-
sponse to an increase in phosphate uptake, to an increase in
phosphataemia, or to an increase in serum calcitriol. Simi-
lar to PTH, FGF23 increases renal phosphate excretion by
inducing the endocytosis and the degradation of sodium/
phosphate co-transporters in the proximal tubule. FGF23
binds to FGF receptors whose specificity for FGF23 de-
pends on the presence of the transmembrane protein αK-
lotho (here named Klotho). The Klotho protein is mainly
expressed in the distal tubule, and to some extent in the
proximal tubule [25]. Klotho, in addition to being a co-
receptor for FGF23 activity, also has direct phosphaturic
properties related to the activity of its cleaved form [26].
Interestingly, the absence of Klotho in mice recapitulates
many of the extra-renal phenotype of CKD, and this has
been related directly to phosphate retention [27, 28].
In response to phosphate retention due to decreased GFR,
the FGF23 circulating level increases from the early stages
of the disease, which leads to increased tubular phosphate
excretion [29]. FGF23 also decreases 1,25-hydroxylation
of vitamin D while increasing calcitriol catabolism, result-
ing in a decrease in circulating calcitriol levels [30]. PTH
increases later than FGF23 during the course of CKD, in
response to low calcitriol levels and hyperphosphataemia/
hypocalcaemia. These compensatory mechanisms tend to
maintain normal phosphataemia by increasing phosphate
tubular excretion and decreasing intestinal absorption until
the late stages of the disease. However, with advancing
kidney disease, phosphate accumulation still occurs. Phos-
phate accumulation promotes cardiovascular disease by
direct toxic effect on endothelial cells [31]. In addition,
FGF23 elevation, although needed to control phos-
phataemia, is also known to directly induce cardiac hyper-
trophy [32, 33]. Finally, renal Klotho expression decreases
early during CKD, leading to a resistance to FGF23, which
participates in decreased phosphate excretion. In addition
to phosphate retention, the decrease in the soluble Klotho,
which possesses antiproliferative properties, may also pro-
mote cardiac hypertrophy and CKD progression [25, 34,
35].
Altogether, adaptations observed in CKD aim mainly to
maintain normal phosphataemia. However, these mecha-
nisms are not sufficient in advanced CKD, where phos-
phate accumulation occurs and participates in cardiovas-
cular disease. Compensatory mechanisms, such as FGF23
and PTH elevation, although crucial to avoiding phosphate
accumulation in early CKD stages, also promote heart hy-
pertrophy and bone disease in CKD patients.
Modulating mineral metabolism and its effect
on cardiac and renal disease
The majority of CKD patients will experience cardiovas-
cular events, and eventually die before reaching end-stage
renal disease. This observation leads us to consider cardio-
vascular disease as a high-priority problem in CKD. Al-
though a large part of cardiovascular prevention will al-
ways rely on the control of traditional risk factors, such as
diabetes and hypertension, some new avenues may open.
Maintaining normal phosphataemia is one of the current
targets of nephrological care and relies mainly on the use
of phosphate binders. However, this intervention is rather
late and its efficiency still debated, whereas compliance is
low due to the high number of pills needed. New leads in-
clude the decrease of gut phosphate absorption by trans-
porter inhibitors such as tenapanor, which may increase pa-
tients’ compliance by reducing the burden of pills needed.
Experimentally, it has been demonstrated that neutralising
anti FGF23-Ab in CKD rats increases mortality and aortic
calcifications, potentially due to a dose-dependent increase
in serum phosphate [36]. Targeting FGF23 to decrease
heart hypertrophy may thus require more specific targets
[33]. Therefore, another promising target in CKD seems to
be the restoration of Klotho levels. Restoring Klotho lev-
els, either by over-expressing the protein or administrating
a soluble form of the protein, appears sufficient in experi-
ments to slow renal disease progression, improve heart hy-
pertrophy and calcifications, and decrease phosphataemia
[37–39]. This may therefore become a novel therapeutic
avenue in CKD patients. From this point of view, under-
standing Klotho regulation during early and late CKD is of
crucial importance.
A potential link between albuminuria and
phosphate retention
Given the important role of phosphate homeostasis during
CKD, and the predictive role of albuminuria for cardiovas-
cular events, we hypothesised in our work which received
the Pfizer price and was published in the Journal of the
American Society of Nephrology, that deficient phosphate
excretion and albuminuria could be related [40].
We thus based our study on the hypothesis that albuminuria
could be directly related to cardiovascular disease by pro-
moting renal phosphate retention (fig. 1). This was moti-
vated by recent observations showing that FGF23 levels
are higher in children with glomerular (hence albuminuric)
versus tubular disease [41]. In IgA nephropathy, FGF23
was also demonstrated to be higher in albuminuric patients
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Figure 1: Pathway by which proteinuria increases cardiovascular
mortality.
[42]. Quite interestingly, the predictive value of albumin
and decreased eGFR for cardiovascular disease was no
longer significant when correcting for elevation of FGF23
in the CRIC study of CKD patients, suggesting a link be-
tween albuminuria and FGF23 elevation [43]. At the mole-
cular level, NPT2a endocytosis and subsequent lysosomal
degradation requires a functional megalin/cubulin system,
which is also used by albumin for endocytosis in the prox-
imal tubule [44]. Finally Klotho down-regulation is de-
scribed as an early event in CKD, long before renal func-
tion declines [45].
We therefore hypothesised that albuminuria could promote
tubular phosphate retention independently of GFR decline,
either by a competitive mechanism in the proximal tubule,
or via Klotho regulation and a resistance to FGF23 action
(fig. 2). To verify this hypothesis, we used different exper-
imental approaches.
We first studied phosphate handling in children presenting
acute nephrotic syndrome both in the nephrotic phase and
in remission of the disease. We observed that, although
eGFR was not altered in this setting, phosphate levels and
FGF23 levels were higher during the nephrotic (protein-
uric) phase compared to remission. We then studied the as-
sociation between phosphataemia and albuminuria levels
in a large cohort of CKD patients, the Nephrotest cohort
in Paris. In 1,738 patients suffering from CKD at differ-
ent stages, we did observe that the presence of albuminuria
was associated with higher phosphate levels independently
of other determinants for phosphataemia, including mea-
sured GFR. Circulating FGF23 concentrations, which were
assessed in a subset of 397 patients, were also higher in
the presence of albuminuria, independently of GFR. This
implies that, despite higher FGF23, the presence of albu-
minuria is sufficient to impair renal phosphate excretion,
leading to increased serum phosphate, and independently
of renal function.
We further studied the molecular mechanisms of these ob-
servations in vivo, in two models of proteinuria in the rat
and the mouse, as well as in vitro in cultured proximal
tubule derived cells. Briefly, we demonstrated that protein-
uric animals displayed higher levels of the sodium phos-
phate transporter NPT2a, despite higher FGF23 and PTH
levels. The FGF23 downstream pathway was also down-
regulated in the two models of proteinuric animals, sug-
gesting a resistance to FGF23. This was seen together with
a decrease in renal Klotho protein expression in both ani-
mal models. Finally, in cultured cells, albumin had no ap-
Figure 2: Molecular pathway linking albuminuria to phosphate retention. NaPi-II: sodium phosphate co-transporter type IIa, PTHR1: PTH re-
ceptor 1; FGFR: FGF receptor.
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parent direct effect on phosphate transport. These experi-
mental data confirmed a tubular impairment in phosphate
excretion in the presence of albuminuria. The absence of
albumin effect on cultured cells suggests that this defect
does not rely on a direct competitive effect of albumin on
phosphate absorption in the proximal tubule. Rather, albu-
minuria impaired FGF23 downstream pathway, probably
due to a decrease in the Klotho protein, a major FGF23 co-
factor and a regulator of phosphate excretion.
Altogether, these data confirm that modifications of albu-
minuria directly alter tubular phosphate handling by the
kidney, leading to phosphate retention despite FGF23 ele-
vation. Since both phosphataemia and FGF23 levels are as-
sociated with cardiovascular mortality, these observations
substantiate a direct pathophysiological link between the
presence of albumin in the urine, and the excessive cardio-
vascular mortality.
Perspectives
Our work has several strengths. We were able to confirm
our hypothesis in the clinical setting, both in adults and
children. We then used animals and cell models to study
the pathways involved. These approaches confirmed the
relevance of our observations.
Several questions remain unanswered and would deserve
further study: Is the regulation of FGF23, Klotho and phos-
phate sufficient to explain the high cardiovascular mortali-
ty associated directly with albuminuria? This appears to be
the case in the large CRIC study, but other cohorts would
be necessary to confirm this data [43]. In children, several
studies confirm our observation that nephrotic proteinuria
is associated with higher phosphate levels [46]. Some stud-
ies further demonstrate that vascular rigidity is increased
during childhood nephrotic syndrome [47]. The impact of
such observations on later cardiovascular risk is however
unknown. At the molecular level, the pathway by which
albumin regulates Klotho protein expression also deserves
further study. Indeed, targeting Klotho in albuminuric dis-
ease may be of great therapeutic interest.
Altogether, our published work links albuminuria to phos-
phate retention and FGF23 elevation [48] for the first time.
It confirms that some of so called “biomarkers” of disease
often play a crucial pathophysiological role, which ex-
plains their predictive value. Although more clinical and
fundamental observations are needed to deepen these ob-
servations, we believe they may point to new therapeutic
avenues in CKD.
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